NCT03050190View on ClinicalTrials.gov

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

September 1, 2028

Study Completion Date

December 31, 2029

Conditions
B-cell Malignancies
Interventions
GENETIC

Therapeutic 4SCAR19 cells

Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19

Trial Locations (2)

518000

RECRUITING

Shenzhen Geno-immune Medical Institute, Shenzhen

650000

RECRUITING

The First People's Hospital of Yunnan, Kunming

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER